Table 3. Cytotoxicity of the Bis-substituted Tetrandrine Derivatives Studied Herein against Human Cancer Cell Lines and Retinal Epithelium Cellsa.
| compound | HeLa | LS-180 | A-549 | ARPE-19 |
|---|---|---|---|---|
| tetrandrine | 16.64 ± 0.02 (26.72 ± 0.03) | 6.43 ± 0.34 (10.33 ± 0.55) | 12.07 ± 1.51 (19.38 ± 2.42) | 8.45 ± 0.19 (13.57 ± 0.30) |
| BBT | >30.00* (>31.10) | >30.00* (>31.10) | >30.00* (>31.10) | >30.00* (>31.10) |
| BNaphT | >30.00* (>28.18) | >30.00* (>28.18) | 24.23 ± 0.29 (22.76 ± 0.27) | 21.10 ± 1.42 (19.82 ± 1.33) |
| BPyrT | >30.00* (>24.66) | 5.84 ± 0.72 (4.80 ± 0.59) | 17.47 ± 1.05 (14.36 ± 0.86) | 9.23 ± 1.97 (7.59 ± 1.62) |
| BInT | >30.00* (>28.02) | >30.00* (>28.02) | 28.25 ± 3.00 (26.39 ± 2.80) | 28.25 ± 1.49 (26.39 ± 1.39) |
| BAqT | >30.00* (>24.50) | >30.00* (>24.50) | >30.00* (>24.50) | >30.00* (>24.50) |
a
Data are shown as the mean IC50 ± SD (standard deviation) in μg/mL (μM ± SD in parentheses) from three independent repetitions after 48 h exposure to the test compounds. The asterisk (*) represents the maximum concentration tested, which did not reach an IC50 value.